An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
A phase 3 trial of Ivosidenib and Azacitidine in acute myeloid leukaemia, run by Servier Affaires Médicales, now recruiting.
Overview
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. is a phase 3 interventional study registered as NCT05907057 by Servier Affaires Médicales, with 245 participants planned, started 2023-06-14 and due to reach its primary completion in 2027-10-15. Interventions recorded: Ivosidenib 500mg Oral Tablet and Azacitidine.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialIvosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Shares Ivosidenib and the tag pipeline.
- TrialAn Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Shares Ivosidenib and the tag pipeline.
- TrialA Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of BGB-11417 in Participants With Myeloid Malignancies
Shares Azacitidine, Acute myeloid leukaemia and the tag pipeline.